Power3 Medical Products, Inc. (OTC.BB:PWRM) a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced that it delivered four poster presentations at the 2010 International Conference on Alzheimer�s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro�, Power3�s diagnostic test, and focused on Power3�s Alzheimer�s disease blood serum biomarkers, test and clinical validation trials.
Power3 leverages its knowledge of proteomics to detect diseases earlier than currently thought possible. The focus of Power3�s efforts is on developing very sensitive patient tests that will enable doctors to diagnose and treat a disease before it becomes life-threatening or debilitating.
Every 72 seconds someone in America will develop Alzheimer�s. Current estimate that 5.1Million Americans have Alzheimer�s. Almost 10 Million Americans caring for Alzheimer�s disease or related dementia.
1 in every 8 women will develop breast cancer According to the World Health Organization, more than 1.2 million people will be diagnosed with breast cancer each year worldwide and over 500,000 will die from the disease.
Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer�s disease, Parkinson�s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig�s disease).
Eline Entertainment Group, Inc. (PINK SHEETS:EEGI) released a statement from Mr. Sheng Chen, CEO of subsidiary Vu365:
�We at Vu365 are thrilled to team with EEGI. The web and casual gaming industry is one of the fastest growing leisure market sectors worldwide. Ours is an exciting company with a top-quality product that is only growing in popularity through the boom in online gaming. We expect this partnership with EEGI to raise the value of our company, as we are now able to expand our software development efforts to add to our already successful list of popular video game titles. We fully expect our existing revenues, currently in the $2 million USD range, to rise as the various projects we have in development, including an assortment of strategic web games, cyber games and 3-D large scale competitive games, land in the marketplace. These are exciting times for Vu365, and we look forward to a successful partnership with EEGI.�
Vu365 has been looking to enter the US market for quite some time, and this merger is the perfect opportunity. According to sources, Vu365 offers revenues in the $2 million USD range, with profits of $500,000 USD.
Vu365 is a popular China-based video game designing company. Founded in 2005, the group designs online and casual video games including strategic web games, cyber games and 3D large scale competitive games and has several products in development.
EEGI will keep investors updated as to future news from Vu365.
Fronteer Gold Inc (AMEX:FRG) announced that core drilling adjacent to, and beneath, historic pits at the company�s wholly owned Northumberland gold deposit has returned excellent grades over significant widths. Fronteer Gold�s goal is to advance Northumberland as a combined open-pit and underground operation. The majority of the drilling conducted to date by Fronteer Gold has focused on defining high-grade domains of underground-mineable sulphide gold mineralization, which are now in the process of being accessed via a 280-metre decline.
Fronteer Development Group Inc. engages in the acquisition, exploration, and development of mineral resource properties in Canada, the United States, Mexico, and Turkey.
Accelr8 Technology Corp. (AMEX:AXK) announced that it extended its technology evaluation agreement for its BACcel� rapid diagnostic system with a global diagnostics company. The original agreement was announced on June 17, 2010. The essential terms remain unchanged and continue the funding to Accelr8 during the extended project period. The amended agreement culminates no later than mid-2011. The project includes analysis of ongoing pre-clinical and pilot studies at the Denver Health Medical Center, and at the Barnes-Jewish Hospital in St. Louis (the Washington University in St. Louis School of Medicine). It also specifies certain technical milestones for product engineering and test kit development.
Accelr8 Technology Corporation develops materials and instrumentation for applications in medical instrumentation, basic research, drug discovery, and bio-detection in the United States.
Northern Oil and Gas, Inc. (AMEX:NOG) announced that it has completed the sale of 8,950,000 shares of its common stock and that the underwriters have exercised their over-allotment option to purchase an additional 1,342,500 shares of Northern Oil’s common stock in full. As a result, Northern Oil has issued a total of 10,292,500 shares of its common stock. The net proceeds from the offering are approximately $200.1 million after deducting underwriters discounts.
Northern Oil and Gas, Inc. engages in the acquisition, exploration, exploitation, and development of oil and natural gas properties in the Rocky Mountain region of the United States.
No comments:
Post a Comment